15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering DiaMedica Therapeutics Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $12.00 to $25.00 (about 2.1x), a sign of real disagreement on valuation. The average target of $18.50 sits 175% above the current $6.72. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.21 next quarter toward $-0.88 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to DiaMedica Therapeutics Inc.
As of Jul, 2 of 2 firms rate DMAC a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
DMAC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.21
Range $-0.24 – $-0.19 · 4 analysts · +25% YoY
Next period, 4 analysts expect DiaMedica Therapeutics Inc to earn $-0.21 a share (range $-0.24 – $-0.19), versus $-0.17 a year earlier. Full-year consensus is $-0.83, growing to $-0.88 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering DiaMedica Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DMAC.
#1
Chase Knickerbocker
Craig-Hallum · Rank #25
Buy
$11.00+63.7% to target
Overall win rate
58%
+ Follow
#2
MC
Matthew Caufield
HC Wainwright & Co. · Rank #51
Buy
$12.00+78.6% to target
Overall win rate
56%
+ Follow
#3
Josh Schimmer
Cantor Fitzgerald · Rank #140
Buy
$25.00+272.0% to target
Overall win rate
38%
+ Follow
#4
Francois Brisebois
Oppenheimer · Rank #186
Buy
$6.00-10.7% to target
Overall win rate
40%
+ Follow
#5
SK
Stacy Ku
TD Cowen
Buy
No targeton DMAC
Coverage
—
+ Follow
DMAC stock forecast FAQ
What is DMAC's average 12-month price target?+
The 2 analysts with a live target average $18.50 for DiaMedica Therapeutics Inc over the next 12 months, ranging from a $25.00 high to a $12.00 low.
Is DMAC stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for DMAC?+
The Street-high target is $25.00 (Cantor Fitzgerald), and the Street-low is $12.00 (HC Wainwright & Co.). The average of all 2 active targets is $18.50.
How many Wall Street analysts cover DMAC?+
2 analysts have an active rating on DiaMedica Therapeutics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering DMAC?+
Among analysts who currently cover DMAC, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #25). Their current call is Buy with a $11.00 target.
What is DiaMedica Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.21 per share (range $-0.24 – $-0.19) across 4 analysts. Full-year EPS is projected at $-0.83, rising to $-0.88 the following year.
How much revenue is DiaMedica Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading DMAC lately?+
As of Jul, 2 of 2 firms rate DMAC a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DMAC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
